arBtrage CAPITALIZING MARKETS — checking… Sign in Sign up
Calendar /

Insmed Incorporated

INSM Health Care Biotechnology: Pharmaceutical Preparations
$126.29
Today
as of Sep 4, 16:50 ET
Last 30 days +21.28% Jul 28 → Sep 04
$95.55 $106.07 $116.60 $127.13 $137.65 Jul 28 Aug 05 Aug 12 Aug 20 Aug 27 Sep 04
Open
$126.00
High
$128.24
Low
$125.62
Volume
$2M
Avg Vol
$3M
Mkt Cap
$27.6B
P/E (TTM)
—
Beta
—
52w High
$212.75
52w Low
$90.39
Div Yield
—
Shares Out
$218M

Recent Press Releases & News last 60 days · 25 items

mixed ▲ 1 ● 20 ▼ 0
Sep 4 · 11:00 PR PR Newswire neutral
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Sep 3 · 11:00 PR PR Newswire neutral
Insmed to Present Data Across Its Respiratory Portfolio, Including New Late-Breaking ARIKAYCE® (amikacin liposome inhalation suspension) Results From Phase 3b ENCORE Study at the European Respiratory Society Congress 2026
Sep 2 · 16:25 Insider Monkey neutral
Do You Believe in Insmed’s INSM) Long-Term Potential Despite Short-Term Challenges?
▸ Show all 25 press releases & news Free account →

Overview

52-week range
$90
$213
29% of range
Avg surprise (last 3)
-6.5%
Avg reaction (last 2)
-13.6%
0% positive
Latest IV / EM
36%
EM ±5.6% · $125 · Sep 18

Earnings trends

EPS — actual vs estimate Actual Estimate
$-1.94$-1.47$-1.00$-0.53$-0.06 Actual $-1.17Actual $-1.78Actual $-1.11Actual $-1.06Actual $-1.94Actual $-1.27Actual $-1.42Est $-1.36Actual $-1.70Est $-1.30Actual $-1.75Actual $-0.76Est $-0.90Actual $-0.06 MarJunSepMarJunSepMar/2025Jun/2025SepMar/2026Jun
Revenue vs Net Income Revenue Net income
$-370M$-166M$38M$243M$447M Sep 24Mar 25Jun 25Sep 25Mar 26Jun 26

Earnings history

DatePeriodActual EPSEstSurpriseYoY %ΔDay reactSource
Tue Jun 30, 2026Jun 2026 $-0.06 — — — — financials
Thu May 7, 2026Mar/2026 $-0.76 $-0.90 +15.6% +46.5% -23.4% earnings
Tue Sep 30, 2025Sep 2025 $-1.75 — — — — financials
Thu Aug 7, 2025Jun/2025 $-1.70 $-1.30 -30.8% — — earnings
Thu May 8, 2025Mar/2025 $-1.42 $-1.36 -4.4% — -3.9% earnings
Mon Sep 30, 2024Sep 2024 $-1.27 — — — — financials
Sun Jun 30, 2024Jun 2024 $-1.94 — — — — financials
Sun Mar 31, 2024Mar 2024 $-1.06 — — — — financials
Sat Sep 30, 2023Sep 2023 $-1.11 — — — — financials
Fri Jun 30, 2023Jun 2023 $-1.78 — — — — financials
Fri Mar 31, 2023Mar 2023 $-1.17 — — — — financials

Financials

Income statement (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue$425M$306M—$142M$107M$93M—$93M
Cost of revenue$67M$47M—$29M$28M$21M—$21M
Gross profit————————
Operating income$-2M$-153M—$-366M$-313M$-248M—$-213M
Net income$-13M$-164M—$-370M$-322M$-257M—$-221M
EPS (diluted)$-0.06$-0.76—$-1.75$-1.70$-1.42—$-1.27

Balance sheet (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Cash & equivalents$545M$582M$510M$335M$1.28B$403M$555M$461M
Inventory$142M$133M$132M$121M$108M$101M$99M$98M
Total current assets$1.63B$1.61B$1.79B$1.93B$2.08B$1.40B$1.62B$1.65B
Total assets$2.10B$2.08B$2.26B$2.36B$2.48B$1.80B$2.03B$2.05B
Long-term debt$544M$542M$541M$540M$539M$1.11B$1.10B$955M
Total liabilities$1.35B$1.37B$1.53B$1.42B$1.23B$1.70B$1.74B$1.57B
Total equity$757M$705M$739M$946M$1.25B$99M$285M$483M

Implied volatility — last 90 days

29%86%142%198%255% Jun 07 — IV 67% · EM ±9.3%Jun 08 — IV 68% · EM ±9.0%Jun 09 — IV 65% · EM ±8.1%Jun 10 — IV 71% · EM ±8.3%Jun 11 — IV 60% · EM ±6.6%Jun 12 — IV 61% · EM ±6.3%Jun 15 — IV 72% · EM ±5.2%Jun 16 — IV 66% · EM ±3.9%Jun 17 — IV 100% · EM ±4.2%Jun 19 — IV 54% · EM ±12.0%Jun 22 — IV 58% · EM ±12.1%Jun 23 — IV 57% · EM ±11.7%Jun 24 — IV 55% · EM ±11.1%Jun 25 — IV 53% · EM ±10.4%Jun 26 — IV 57% · EM ±10.9%Jun 29 — IV 58% · EM ±10.3%Jun 30 — IV 56% · EM ±9.6%Jul 01 — IV 52% · EM ±8.7%Jul 02 — IV 61% · EM ±9.9%Jul 03 — IV 63% · EM ±9.9%Jul 06 — IV 61% · EM ±8.5%Jul 07 — IV 58% · EM ±7.7%Jul 08 — IV 61% · EM ±7.7%Jul 09 — IV 64% · EM ±7.6%Jul 10 — IV 57% · EM ±6.3%Jul 13 — IV 69% · EM ±5.7%Jul 14 — IV 59% · EM ±4.3%Jul 15 — IV 69% · EM ±4.1%Jul 16 — IV 178% · EM ±7.4%Jul 20 — IV 63% · EM ±15.0%Jul 21 — IV 64% · EM ±14.8%Jul 22 — IV 60% · EM ±13.8%Jul 23 — IV 64% · EM ±14.3%Jul 24 — IV 68% · EM ±15.0%Jul 27 — IV 70% · EM ±14.5%Jul 28 — IV 72% · EM ±14.7%Jul 29 — IV 67% · EM ±13.3%Jul 30 — IV 69% · EM ±13.5%Jul 31 — IV 73% · EM ±13.9%Aug 03 — IV 79% · EM ±14.0%Aug 04 — IV 78% · EM ±13.4%Aug 05 — IV 89% · EM ±14.8%Aug 06 — IV 43% · EM ±7.0%Aug 07 — IV 37% · EM ±5.8%Aug 10 — IV 38% · EM ±5.2%Aug 11 — IV 255% · EM ±33.7%Aug 12 — IV 38% · EM ±4.7%Aug 13 — IV 36% · EM ±4.2%Aug 14 — IV 37% · EM ±4.1%Aug 17 — IV 49% · EM ±4.1%Aug 18 — IV 41% · EM ±3.0%Aug 19 — IV 41% · EM ±2.4%Aug 20 — IV 92% · EM ±3.8%Aug 24 — IV 38% · EM ±7.9%Aug 25 — IV 34% · EM ±7.0%Aug 26 — IV 33% · EM ±6.6%Aug 27 — IV 30% · EM ±5.9%Aug 28 — IV 33% · EM ±6.2%Aug 31 — IV 35% · EM ±6.2%Sep 01 — IV 30% · EM ±5.1%Sep 02 — IV 36% · EM ±6.1%Sep 03 — IV 37% · EM ±6.0%Sep 04 — IV 36% · EM ±5.6%

Sector peers

LLY
Eli Lilly and Company
$1.1T $1,148.00-0.1%
JNJ
Johnson & Johnson
$671.0B $275.71+0.2%
ABBV
AbbVie Inc.
$430.9B $256.50+0.1%
MRK
Merck & Company, Inc.
$317.1B $150.33+0.0%
PM
Philip Morris International Inc
$299.3B $182.53+0.0%
NVS
Novartis AG
$297.9B $155.11-3.0%
View on Nasdaq ↗
🔒 Preview mode. Create a free account to unlock the full earnings calendar, all panels, heatmaps, options flow, and screener.
Sign up free → Sign in